2024
Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover D, Gatti‐Mays M, Pariser A, Sudheendra P, George M, Lustberg M. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine 2024, 13: e7317. PMID: 38895891, PMCID: PMC11185945, DOI: 10.1002/cam4.7317.Peer-Reviewed Original ResearchConceptsOvarian suppressionEndocrine therapyAdjuvant endocrine therapyBreast cancerClinicopathological featuresAromatase inhibitorsOS useHR+/HER2+ breast cancerOptimal adjuvant endocrine therapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Real-world treatment patternsCohort of premenopausal womenAnti-HER2 therapyPremenopausal breast cancerClinicopathological risk factorsMultivariable logistic regression assessed associationsLogistic regression assessed associationsPremenopausal BCPrescribed tamoxifenPremenopausal patientsPremenopausal womenBC subtypesContemporary cohortAnti-HER2
2021
Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Research And Treatment 2021, 190: 183-188. PMID: 34498153, PMCID: PMC8560558, DOI: 10.1007/s10549-021-06368-4.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalBreast NeoplasmsChemotherapy, AdjuvantFemaleGonadotropin-Releasing HormoneGoserelinHumansPatient PreferencePremenopauseTamoxifenConceptsOvarian function suppressionPositive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerBreast cancerPremenopausal womenPatient preferencesPremenopausal Hormone Receptor-Positive Breast CancerAdjuvant gonadotropin‐releasing hormone analoguesHR-positive breast cancerGonadotropin-releasing hormone analogueDiscontinuation of GnRHaThird of patientsChi-square testMonthly goserelinClinical characteristicsTreatment toxicityVaginal drynessClinicopathologic characteristicsGnRH analoguesHot flashesSurgical ablationResultsA totalMedical recordsGnRHaDelay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer
Vaughn JE, Ammermann C, Lustberg MB, Bickel WK, Stein JS. Delay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer. Health Psychology 2021, 40: 398-407. PMID: 34323542, DOI: 10.1037/hea0001077.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalBreast NeoplasmsChemotherapy, AdjuvantCross-Sectional StudiesDelay DiscountingFemaleHumansMedication AdherenceConceptsEndocrine therapy adherenceTherapy adherenceHormone receptor-positive breast cancerAdjuvant endocrine therapy adherenceReceptor-positive breast cancerOral endocrine therapyBreast cancer survivorsBreast cancer patientsSelf-reported adherencePatient-centered factorsBrief behavioral interventionCross-sectional associationsPotential therapeutic targetMaladaptive health behaviorsEndocrine therapyMedication nonadherenceCancer survivorsCancer patientsRisk factorsBreast cancerTherapeutic targetHealth behaviorsPatientsBehavioral interventionsSurvivorsGenomic features of rapid versus late relapse in triple negative breast cancer
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorChemotherapy, AdjuvantDatasets as TopicDisease-Free SurvivalDNA Copy Number VariationsFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLogistic ModelsMastectomyMiddle AgedModels, GeneticMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRisk AssessmentTime FactorsTriple Negative Breast NeoplasmsConceptsLate relapseRapid relapseImmune signaturesBreast cancerAnti-tumor CD8 T cellsBackgroundTriple-negative breast cancerTriple-negative breast cancerCD8 T cellsTumor mutation burdenIndependent validation cohortNegative breast cancerFisher's exact testPearson's chi-squared testChi-squared testLogistic regression modelsLuminal signaturePrimary TNBCTNBC subsetImmune subsetsClinical featuresValidation cohortWhole-genome copy numberPrimary tumorM1 macrophagesT cells
2017
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Wesolowski R, Duggan M, Stiff A, Markowitz J, Trikha P, Levine K, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae E, Lustberg M, Reinbolt R, Mrozek E, Byrd J, Caligiuri M, Mace T, Carson W. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunology, Immunotherapy 2017, 66: 1437-1447. PMID: 28688082, PMCID: PMC5647220, DOI: 10.1007/s00262-017-2038-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBlack or African AmericanBreast NeoplasmsCell CountChemotherapy, AdjuvantCyclophosphamideCytokinesDoxorubicinFemaleGranulocytesHumansMiddle AgedMonocytesMyeloid-Derived Suppressor CellsNeoadjuvant TherapyPaclitaxelPilot ProjectsTreatment OutcomeWhite PeopleConceptsMyeloid-derived suppressor cellsPathologic complete responseG-MDSC levelsNeo-adjuvant chemotherapyG-MDSCSuppressor cellsComplete responseAnti-HER2 therapyPeripheral blood levelsBreast cancer patientsAfrican American patientsBreast cancer typesCyclophosphamide therapyBlood levelsCancer patientsLast administrationAmerican patientsBreast cancerPatientsFlow cytometryCancer typesChemotherapySignificant riseConfidence intervalsCycle 1
2015
Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach
Reinbolt R, Mangini N, Hill J, Levine L, Dempsey J, Singaravelu J, Koehler K, Talley A, Lustberg M. Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach. Seminars In Oncology Nursing 2015, 31: 146-155. PMID: 25951743, DOI: 10.1016/j.soncn.2015.02.002.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantEndocrine SystemFemaleHumansNeoplasm MetastasisOncology NursingTamoxifenConceptsEndocrine therapyBreast cancerMetastatic breast cancer settingLong-term disease outcomesHormone-positive breast cancerBreast cancer settingPositive breast cancerNeoadjuvant therapyTherapy adherenceClinical guidelinesSymptom interventionCancer settingDisease outcomeClinical considerationsOptimal durationNursing practiceTherapyCancerAdditional researchPivotal roleTreatmentNational statisticsNeoadjuvantAdjuvantSymptomsAssociation of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer
Oostra D, Lustberg M, Reinbolt R, Pan X, Wesolowski R, Shapiro C. Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer. Molecular And Cellular Endocrinology 2015, 402: 51-56. PMID: 25575458, PMCID: PMC4316829, DOI: 10.1016/j.mce.2014.12.028.Peer-Reviewed Original ResearchConceptsBone mineral densityRapid bone lossFollicle stimulating hormoneBone lossAdjuvant chemotherapyOPG levelsFemoral neckBone resorptionBreast cancerLumbar spineStage I/II breast cancerLS bone mineral densityEarly-stage breast cancerAssociation of osteoprotegerinMonths of amenorrheaMIU/mLNegative pregnancy testNuclear factor kappaChemotherapy initiationPremenopausal womenFSH levelsOsteoclast activationMineral densityStimulating hormonePregnancy test
2012
Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer
Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp M. Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer. Magnetic Resonance Imaging 2012, 30: 1059-1067. PMID: 22884756, PMCID: PMC3645932, DOI: 10.1016/j.mri.2012.04.026.Peer-Reviewed Original ResearchConceptsPotential imaging markerPathologic responseBreast cancerTumor heterogeneityImaging markerHER-2 negative breast cancerImaging biomarkersVolumetric biomarkersCombination neoadjuvant chemotherapyCurrent imaging studiesGood predictive biomarkerNegative breast cancerTherapeutic response assessmentNovel imaging biomarkersNeoadjuvant chemotherapyRetrospective studyPredictive biomarkersNovel biomarkersResponse assessmentHeterogeneous diseaseEarly changesImaging studiesBiomarkersCancerCellular composition